Rationale
Peripheral arterial disease (PAD) is a clinical manifestation of extra-coronary atherosclerosis. Despite sharing the same risk factors, only 20–30% of patients with coronary artery disease (CAD) develop PAD. Declines in the number of bone-marrow derived circulating progenitor cells (PCs) is thought to contribute to the pathogenesis of atherosclerosis. Whether specific changes in PCs differentiate patients with both PAD and CAD from those with CAD alone is unknown.
Objective
Determine whether differences exist in PCs counts of CAD patients with and without known PAD.
Methods and Results
1497 patients (mean age 65, 62% male) with known CAD were identified in the Emory Cardiovascular Biobank. Presence of PAD (n=308) was determined by history, review of medical records or imaging, and was classified as carotid (53%), lower extremity (41%), upper extremity (3%) and aortic disease (33%). Circulating PCs were enumerated by flow cytometry. Patients with CAD and PAD had significantly lower PC counts compared to those with only CAD. In multivariable analysis, a 50% decrease in CD34+ or CD34+/VEGFR2+ counts were associated with a 31% (P=0.032) and 183% (P=0.002) increase in the odds of having PAD, respectively. CD34+ and CD34+/VEGFR2+ counts significantly improved risk prediction metrics for prevalent PAD. Low CD34+/VEGFR2+ counts were associated with a 1.40-fold (95%CI, 1.03, 1.91) and a 1.64-fold (95%CI 1.07, 2.50) increase in the risk of mortality and PAD-related events, respectively.
Conclusions
PAD is associated with low CD34+ and CD34+/VEGFR2+ PC counts. Whether low PC counts are useful in screening for PAD needs to be investigated.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.